• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed...

cafead

Administrator
Staff member
  • cafead   Jun 07, 2022 at 12:02: AM
via Bristol Myers Squibb laid out some big plans over the last couple of years for its Celgene-acquired anemia drug Reblozyl, forecasting a $4 billion-plus peak sales estimate on the back of several potential label expansions.

article source
 

<